← Eichor
Study identifier: NCT06987292 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)

Condition: Psoriasis (PsO) · Enthesitis · Psoriasis Arthritis  ·  Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

It is an observational, single-center, prospective, exploratory, open-label study to assess the efficacy and safety of IL-17 inhibitors on subclinical enthesitis in patients with moderate to severe psoriasis with subclinical enthesitis based on Power Doppler (PD) Ultrasonography (PDUS)

This description comes directly from the study's public registry record.

Talk to the study team

Wenjun Hou, Dr  ·  + 86 135 8402 3320  ·  hwjnanjing@126.com

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Dermatology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNanjing, Jiangsu, ChinaRecruiting
Department of Dermatology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06987292